Vanda Pharmaceuticals Inc.  

(Public, NASDAQ:VNDA)   Watch this stock  
Find more results for VNDA
7.58
-0.36 (-4.53%)
Real-time:   9:53AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.57 - 8.10
52 week 6.91 - 14.50
Open 7.99
Vol / Avg. 8,161.00/677,357.00
Mkt cap 328.68M
P/E     -
Div/yield     -
EPS -0.94
Shares 42.82M
Beta 1.68
Inst. own 103%
May 4, 2016
Q1 2016 Vanda Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 10, 2016
Q4 2015 Vanda Pharmaceuticals Inc Earnings Call - Webcast
Feb 10, 2016
Q4 2015 Vanda Pharmaceuticals Inc Earnings Release
Feb 2, 2016
Vanda Pharmaceuticals Inc at Canaccord Genuity Rare Disease and BioPharma One-on-One Day
Jan 11, 2016
Preliminary Q4 2015 Vanda Pharmaceuticals Inc Earnings Release
Dec 2, 2015
Vanda Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 19, 2015
Vanda Pharmaceuticals Inc at Jefferies Autumn Global Healthcare Conference
Nov 16, 2015
Vanda Pharmaceuticals Inc at Brean Capital Life Sciences Summit Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -46.46% -36.27%
Operating margin -46.76% -36.56%
EBITD margin - -24.76%
Return on average assets -27.38% -20.72%
Return on average equity -42.55% -27.13%
Employees 112 -
CDP Score - -

Address

Suite 300E, 2200 Pennsylvania Ave NW
WASHINGTON, DC 20037
United States - Map
+1-202-7343400 (Phone)
+1-202-2961450 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company's product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. HETLIOZ (tasimelteon) is a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) for which a New Drug Application (NDA) was approved by the United States Food and Drug Administration (FDA). Fanapt (iloperidone) is a product for the treatment of schizophrenia. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is under clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Officers and directors

H. Thomas Watkins Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Mihael H. Polymeropoulos M.D. President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
James Patrick Kelly Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
Richard L Gulino Senior Vice President, General Counsel, Secretary
Bio & Compensation  - Reuters
Paolo Baroldi M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 64
Bio & Compensation  - Reuters
Gian Piero Reverberi Senior Vice President, Acting Chief Commercial Officer and European General Manager
Bio & Compensation  - Reuters
Kenneth M. Bate Director
Age: 65
Bio & Compensation  - Reuters
Michael F. Cola Independent Director
Age: 55
Bio & Compensation  - Reuters
Richard W. Dugan Independent Director
Age: 73
Bio & Compensation  - Reuters
Vincent J. Milano Independent Director
Age: 51
Bio & Compensation  - Reuters